|

IASO207 Injection Clinical Trials

2 actively recruiting trials

Pipeline

Early 1: 2

Top Sponsors

  • Peking University People's Hospital2

Indications

  • Refractory Systemic Lupus Erythematosus1
  • Lupus1
  • Malignancies1
  • Cancer1

Other2 trials

IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)
Early 1
IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.